Literature DB >> 15731071

Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo.

Russell E Vance1, Arne Rietsch, John J Mekalanos.   

Abstract

Pseudomonas aeruginosa uses a dedicated type III secretion system to deliver toxins directly into the cytoplasm of host cells. While progress has been made in elucidating the function of type III-secreted toxins in vitro, the in vivo functions of the type III-secreted exoenzymes are less well understood, particularly for the sequenced strain PAO1. Therefore, we have systematically deleted the genes for the three known type III effector molecules (exoS, exoT, and exoY) in P. aeruginosa PAO1 and assayed the effect of the deletions, both singly and in combination, on cytotoxicity in vitro and in vivo. We found that the type III secretion system acts differently on different cell types, causing an exoST-dependent rounding of a lung epithelial-like cell line in contrast to causing an exoSTY-independent but translocase (popB)-dependent lysis of a macrophage cell line. We utilized an in vivo competitive infection model to test each of our mutants, examining replication in the lung and spread to secondary sites such as the blood and spleen. Type III mutants inoculated intranasally exhibited only a minor defect in replication and survival in the lung, but popB and exoSTY triple mutants were profoundly defective in their ability to spread systemically. Intravenous injection of the mutants indicated that the type III secretion machinery is required for survival in the blood. Furthermore, our findings suggest that the effector-independent popB-dependent cytotoxicity that we and others have observed in vitro in macrophage cell lines may not be of great importance in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731071      PMCID: PMC1064930          DOI: 10.1128/IAI.73.3.1706-1713.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  The N-terminal domain of Pseudomonas aeruginosa exoenzyme S is a GTPase-activating protein for Rho GTPases.

Authors:  U M Goehring; G Schmidt; K J Pederson; K Aktories; J T Barbieri
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Integration-proficient Pseudomonas aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene fusions.

Authors:  A Becher; H P Schweizer
Journal:  Biotechniques       Date:  2000-11       Impact factor: 1.993

3.  Pseudomonas aeruginosa ExoT is a Rho GTPase-activating protein.

Authors:  R Krall; G Schmidt; K Aktories; J T Barbieri
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Genetic recombination in Pseudomonas aeruginosa.

Authors:  B W HOLLOWAY
Journal:  J Gen Microbiol       Date:  1955-12

5.  Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections.

Authors:  A Roy-Burman; R H Savel; S Racine; B L Swanson; N S Revadigar; J Fujimoto; T Sawa; D W Frank; J P Wiener-Kronish
Journal:  J Infect Dis       Date:  2001-05-17       Impact factor: 5.226

6.  Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages.

Authors:  D Dacheux; J Goure; J Chabert; Y Usson; I Attree
Journal:  Mol Microbiol       Date:  2001-04       Impact factor: 3.501

7.  How the Pseudomonas aeruginosa ExoS toxin downregulates Rac.

Authors:  M Würtele; E Wolf; K J Pederson; G Buchwald; M R Ahmadian; J T Barbieri; A Wittinghofer
Journal:  Nat Struct Biol       Date:  2001-01

8.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

Review 9.  Pseudomonas aeruginosa exoenzyme S, a bifunctional type-III secreted cytotoxin.

Authors:  J T Barbieri
Journal:  Int J Med Microbiol       Date:  2000-10       Impact factor: 3.473

10.  The arginine finger domain of ExoT contributes to actin cytoskeleton disruption and inhibition of internalization of Pseudomonas aeruginosa by epithelial cells and macrophages.

Authors:  L Garrity-Ryan; B Kazmierczak; R Kowal; J Comolli; A Hauser; J N Engel
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.609

View more
  103 in total

1.  In vitro characterization of multivalent adhesion molecule 7-based inhibition of multidrug-resistant bacteria isolated from wounded military personnel.

Authors:  Anne Marie Krachler; Katrin Mende; Clinton Murray; Kim Orth
Journal:  Virulence       Date:  2012-06-22       Impact factor: 5.882

2.  A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria.

Authors:  Rachel D Hood; Pragya Singh; Fosheng Hsu; Tüzün Güvener; Mike A Carl; Rex R S Trinidad; Julie M Silverman; Brooks B Ohlson; Kevin G Hicks; Rachael L Plemel; Mo Li; Sandra Schwarz; Wenzhuo Y Wang; Alexey J Merz; David R Goodlett; Joseph D Mougous
Journal:  Cell Host Microbe       Date:  2010-01-21       Impact factor: 21.023

Review 3.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

4.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

Authors:  Weihui Wu; Jin Huang; Biyan Duan; David C Traficante; Haeyeon Hong; Martina Risech; Stephen Lory; Gregory P Priebe
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

5.  Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Authors:  Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 6.  Keeping their options open: acute versus persistent infections.

Authors:  S Furukawa; S L Kuchma; G A O'Toole
Journal:  J Bacteriol       Date:  2006-02       Impact factor: 3.490

7.  The importance of the Pseudomonas aeruginosa type III secretion system in epithelium traversal depends upon conditions of host susceptibility.

Authors:  Aaron B Sullivan; K P Connie Tam; Matteo M E Metruccio; David J Evans; Suzanne M J Fleiszig
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

8.  In vitro assays to monitor the activity of Pseudomonas aeruginosa Type III secreted proteins.

Authors:  Stephanie L Rolsma; Dara W Frank
Journal:  Methods Mol Biol       Date:  2014

9.  Pseudomonas aeruginosa uses T3SS to inhibit diabetic wound healing.

Authors:  Josef Goldufsky; Stephen J Wood; Vijayakumar Jayaraman; Omar Majdobeh; Lin Chen; Shanshan Qin; Chunxiang Zhang; Luisa A DiPietro; Sasha H Shafikhani
Journal:  Wound Repair Regen       Date:  2015-07-27       Impact factor: 3.617

10.  A sensitive fluorescence-based assay for the detection of ExoU-mediated PLA(2) activity.

Authors:  Marc A Benson; Katherine M Schmalzer; Dara W Frank
Journal:  Clin Chim Acta       Date:  2009-11-10       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.